One of the most important trends in 2026 is the widespread adoption of risk-based biocompatibility evaluation. Regulators now expect manufacturers to identify biological hazards early, assess risks based on device use and patient exposure, and apply appropriate risk control measures. Biocompatibility is increasingly integrated with ISO 14971 risk management, rather than being treated as a separate activity.

Chemical characterization has become the foundation of modern biocompatibility assessment. Instead of starting with biological testing, manufacturers are focusing on extractables and leachables studies, material composition analysis, and identification of potential toxic substances. This approach supports informed decision-making and reduces unnecessary testing.

Toxicological risk assessment, as described in ISO 10993-17, is now widely used to evaluate patient exposure to chemicals released from medical devices. In 2025, toxicology is playing a larger role in justifying exclusion of animal tests, assessing systemic toxicity risks, and supporting regulatory submissions. This trend improves scientific rigor and regulatory acceptance.

Regulators are strongly encouraging the reduction of animal testing. The 3Rs principle (Replace, Reduce, Refine) is now firmly embedded in biocompatibility evaluation. Manufacturers are increasingly using in vitro testing, in silico modeling, and chemical and toxicological data. Animal testing is conducted only when scientifically necessary.

Another key trend in 2026 is the effective use of existing data. Regulatory authorities encourage manufacturers to leverage previous biocompatibility studies, clinical data, post-market surveillance information, and published scientific literature. This approach reduces duplication and accelerates development timelines.

Regulators are placing greater emphasis on the quality of Biological Evaluation Plans (BEP) and Biological Evaluation Reports (BER). In 2026, strong documentation is expected to be well-structured, clear, risk-based, device-specific, scientifically justified, and aligned with risk management. Poor documentation is a common cause of regulatory delays.

Biocompatibility strategies are becoming more globally harmonized. ISO 10993-1:2025 aligns well with expectations from the US FDA, EU MDR, and other international regulatory authorities. This alignment allows manufacturers to prepare a single robust biocompatibility strategy for multiple markets.

Manufacturers are increasingly involving biocompatibility and toxicology experts early in the development process. Early involvement helps identify potential risks sooner, avoid late-stage design changes, and reduce regulatory delays. This proactive approach improves overall development efficiency.

Biocompatibility is no longer limited to pre-market evaluation. In 2026, regulators expect a lifecycle approach, including pre-market evaluation, post-market surveillance, and periodic review and updates. This ensures continued patient safety throughout the device lifecycle.

Digital tools are increasingly used to manage biocompatibility data, including risk management systems, data traceability tools, and document control platforms. Improved data management enhances consistency and regulatory readiness.